Derek Ward

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Posaconazole for the Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Subjects with HIV Infection

Daniel J. Skiest, José A. Vázquez, Gregory M. Anstead et al. · Clinical Infectious Diseases · 2007 · 164 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +15

Trends in sexually transmitted infections (other than HIV) in older people: analysis of data from an enhanced surveillance system

A.T. Bodley‐Tickell, Babatunde Olowokure, S. Bhaduri et al. · Sexually Transmitted Infections · 2008 · 122 citations · Full text

Veterinary Medicine, Geriatric Medicine, Infectious Diseases +16

Characterization of a bacteriocin produced by Streptococcus thermophilus ST134

Derek Ward, G. A. Somkuti · Applied Microbiology and Biotechnology · 1995 · 49 citations

Life Sciences, Biotechnology, Microbiology +8

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph J. Eron, Chloe Orkin, Douglas Cunningham et al. · Antiviral Research · 2019 · 36 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17